개 아토피 피부염 시장 기회, 성장요인, 업계 동향 분석 및 예측(2026-2035년)

The Global Canine Atopic Dermatitis Market was valued at USD 1.5 billion in 2025 and is estimated to grow at a CAGR of 9.2% to reach USD 3.6 billion by 2035.

The market growth is driven by the rising prevalence of atopic dermatitis in dogs and a growing focus on companion animal healthcare. Increasing awareness among pet owners about their pets' well-being is fueling demand for advanced veterinary dermatology therapies. The market is also benefiting from innovations in veterinary medications, as pet owners and veterinarians seek safe, effective, and targeted treatment options for chronic skin conditions. With the expansion of veterinary infrastructure and specialized clinics in both developed and emerging regions, more dogs are receiving proper diagnosis and treatment. Rising disposable incomes in emerging markets further encourage investments in pet healthcare. As awareness of the importance of preventative and ongoing dermatological care spreads, the canine atopic dermatitis market is witnessing steady and sustained growth across geographies.

Canine atopic dermatitis is a chronic, genetically influenced inflammatory skin disorder caused by hypersensitivity to environmental allergens like dust mites, pollen, mold, or specific foods. The condition triggers an exaggerated immune response, resulting in persistent itching, redness, and recurrent skin and ear infections. The development of innovative veterinary treatments such as monoclonal antibodies and oral therapies has transformed disease management. Monoclonal antibodies offer targeted relief from pruritus and inflammation, while oral therapies provide convenience and efficacy for long-term treatment. Rising knowledge of companion animal health, especially in emerging economies, is driving higher adoption rates and increased investment in veterinary therapeutics.

The glucocorticoids segment generated USD 511.6 million in 2025. These medications, including prednisone and dexamethasone, are highly effective in rapidly alleviating inflammation and itching, making them the preferred choice for severe or acute flare-ups. Their affordability compared to newer targeted therapies supports their continued adoption, particularly in regions with limited access to advanced veterinary care or low pet insurance penetration.

The oral administration segment held a 47.3% share in 2025. Oral medications like oclacitinib and glucocorticoids are favored by pet owners due to ease of use, which improves compliance and ensures consistent treatment. These therapies deliver fast relief for pruritus and inflammation and are effective for both acute and chronic conditions. Targeted oral treatments enhance efficacy by specifically modulating inflammatory pathways, reinforcing their popularity in veterinary dermatology practices.

North America Canine Atopic Dermatitis Market held 41% share and is expected to grow at a 9% CAGR through 2035. Strong veterinary infrastructure, access to innovative dermatology treatments, and widespread adoption of advanced therapies such as monoclonal antibodies are supporting regional market growth. Pet owners' increasing willingness to invest in specialized care and the prevalence of chronic dermatological conditions among dogs further strengthen North America's market leadership.

Key players operating in the Global Canine Atopic Dermatitis Market include AB Science, Boehringer Ingelheim, Ceva, Dechra Veterinary Products, Elanco Animal Health, Kindred Biosciences, Nextmune, Phibro Animal Health Corporation, Toray Industries, Vetoquinol, Virbac, and Zoetis. Companies in the Global Canine Atopic Dermatitis Market are focusing on R&D to develop innovative therapies, including monoclonal antibodies, targeted oral medications, and combination treatments. They are investing in clinical trials to demonstrate safety and efficacy while expanding product portfolios to address different severity levels and breeds. Strategic collaborations with veterinary clinics and distribution partners, along with educational initiatives to increase awareness among pet owners and veterinarians, are central to expanding market reach. Firms are also entering emerging markets and leveraging digital marketing to increase product adoption and improve brand visibility, enhancing their competitive position.

Table of Contents

Chapter 1 Research Methodology

• 1.1 Market scope and definition
• 1.2 Research approach
• 1.3 Quality commitments
  • 1.3.1 GMI AI policy and data integrity commitment
    • 1.3.1.1 Source consistency protocol
• 1.4 Research trail and confidence scoring
  • 1.4.1 Research trail components
  • 1.4.2 Scoring components
• 1.5 Data collection
  • 1.5.1 Partial list of primary sources
• 1.6 Data mining sources
  • 1.6.1 Paid sources
    • 1.6.1.1 Sources, by region
• 1.7 Base estimates and calculations
  • 1.7.1 Revenue share analysis
  • 1.7.2 Base year calculation
• 1.8 Forecast model
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Product trends
  • 2.2.3 Route of administration trends
  • 2.2.4 Distribution channel trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising pet ownership and humanization of pets
    • 3.2.1.2 Increased awareness of skin disorders and advanced treatment options
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Side effect of few medications
    • 3.2.2.2 Off-label use of human drugs
  • 3.2.3 Market opportunities
    • 3.2.3.1 Growing demand and utilization of combination therapies
    • 3.2.3.2 Development of pediatric ulcerative colitis treatment
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape (Driven by primary research)
  • 3.4.1 North America
    • 3.4.1.1 U.S.
    • 3.4.1.2 Canada
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
• 3.5 Pricing analysis (Driven by primary research)
• 3.6 Pipeline and clinical trials landscape
• 3.7 Future market trends
• 3.8 Impact of AI and generative AI on the market
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Glucocorticoids
• 5.3 Antihistamines
• 5.4 Immunosuppressants
• 5.5 MAbs
• 5.6 Other products

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Oral
• 6.3 Topical
• 6.4 Injectable

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Retail pharmacies
• 7.3 Veterinary hospital pharmacies
• 7.4 Online pharmacies

Chapter 8 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Italy
  • 8.3.5 Spain
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 AB Science
• 9.2 Boehringer Ingelheim
• 9.3 Ceva
• 9.4 Dechra Veterinary Products
• 9.5 Elanco
• 9.6 Kindred Biosciences
• 9.7 Nextmune (Vimian)
• 9.8 Phibro Animal Health Corporation
• 9.9 Toray Industries
• 9.10 Vetoquinol
• 9.11 Virbac
• 9.12 Zoetis